GLP-1 RECEPTOR AGONIST AND USE THEREOF
Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonis...
Saved in:
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
20.05.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.
L'invention concerne de nouveaux composés de formule chimique 1, des isomères optiques des composés, et des sels pharmaceutiquement acceptables des composés ou des isomères optiques. Les composés, isomères et sels présentent une excellente activité en tant qu'agonistes du récepteur GLP-1. En particulier, les composés, en tant qu'agonistes du récepteur GLP-1, présentent une excellente tolérance au glucose, ayant ainsi un grand potentiel pour être utilisés en tant qu'agents thérapeutiques pour des maladies métaboliques. De plus, ils présentent une excellente innocuité pharmacologique pour des systèmes cardiovasculaires. |
---|---|
AbstractList | Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.
L'invention concerne de nouveaux composés de formule chimique 1, des isomères optiques des composés, et des sels pharmaceutiquement acceptables des composés ou des isomères optiques. Les composés, isomères et sels présentent une excellente activité en tant qu'agonistes du récepteur GLP-1. En particulier, les composés, en tant qu'agonistes du récepteur GLP-1, présentent une excellente tolérance au glucose, ayant ainsi un grand potentiel pour être utilisés en tant qu'agents thérapeutiques pour des maladies métaboliques. De plus, ils présentent une excellente innocuité pharmacologique pour des systèmes cardiovasculaires. |
Author | IM, A-RANG YOO, YEONGRAN JEONG, JIN AH LEE, MYONG JAE JANG, EUN HYE AN, KYUNG MI KIM, KYEOJIN HONG, CHANGHEE KIM, GUNHEE LEE, JIN HEE KIM, JEONG-GEUN KWON, SUNG WOOK YOON, HONG CHUL CHANG, MIN WHAN JUN, YEARIN KIM, JUNG HO JEON, WOO JIN HONG, DA HAE JE, IN-GYU CHOI, JI HYE OH, CHANGMOK HEO, JAEHO PARK, JUNG-EUN SHIN, JAE EUI SOHN, TE-IK |
Author_xml | – fullname: PARK, JUNG-EUN – fullname: AN, KYUNG MI – fullname: KIM, JEONG-GEUN – fullname: HEO, JAEHO – fullname: YOO, YEONGRAN – fullname: SHIN, JAE EUI – fullname: JEON, WOO JIN – fullname: CHANG, MIN WHAN – fullname: OH, CHANGMOK – fullname: JANG, EUN HYE – fullname: KWON, SUNG WOOK – fullname: LEE, JIN HEE – fullname: KIM, JUNG HO – fullname: IM, A-RANG – fullname: LEE, MYONG JAE – fullname: CHOI, JI HYE – fullname: JUN, YEARIN – fullname: HONG, DA HAE – fullname: JE, IN-GYU – fullname: KIM, KYEOJIN – fullname: HONG, CHANGHEE – fullname: SOHN, TE-IK – fullname: KIM, GUNHEE – fullname: YOON, HONG CHUL – fullname: JEONG, JIN AH |
BookMark | eNrjYmDJy89L5WRQc_cJ0DVUCHJ1dg0I8Q9ScHT39_MMDlFw9HNRCA12VQjxcA1y9XfjYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxzo7GhmYGpoYWjobGRCgBADdKJGg |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | AGONISTE DU RECEPTEUR GLP-1 ET SON UTILISATION |
ExternalDocumentID | CA3160518A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_CA3160518A13 |
IEDL.DBID | EVB |
IngestDate | Fri Aug 30 05:45:56 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_CA3160518A13 |
Notes | Application Number: CA20203160518 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210520&DB=EPODOC&CC=CA&NR=3160518A1 |
ParticipantIDs | epo_espacenet_CA3160518A1 |
PublicationCentury | 2000 |
PublicationDate | 20210520 |
PublicationDateYYYYMMDD | 2021-05-20 |
PublicationDate_xml | – month: 05 year: 2021 text: 20210520 day: 20 |
PublicationDecade | 2020 |
PublicationYear | 2021 |
RelatedCompanies | ILDONG PHARMACEUTICAL CO., LTD |
RelatedCompanies_xml | – name: ILDONG PHARMACEUTICAL CO., LTD |
Score | 3.3279586 |
Snippet | Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | GLP-1 RECEPTOR AGONIST AND USE THEREOF |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210520&DB=EPODOC&locale=&CC=CA&NR=3160518A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT4MwEL8s06hvOjXOr_TB8EakfGzwQAwrZWgcEMbM3pbRQrKXuTiM_74HYdMXfWva5Npe8uvdr9e7AjwUpbFER0Oo9sAxVLMcUBV5FlVzcymktKgsmqy0STQIZ-bL3Jp3YLXLhWnqhH41xRERUQLxXjXn9ebnEstv3lZuH_MVdr0_BZnrKy07Rv5i6Zrij1yexH7MFMZc5ilR6hoU_XZqe0iUDtCLHtZg4G-jOill89uiBKdwmKCwdXUGnWLdg2O2-3itB0eTNt6NzRZ623NQxq-JSknKGU-yOCXeOI6epxnxIp_MppxkIU95HFwACXjGQhUnXOw3t2DefmnGJXSR8xdXQHQpc4cK5F66YQrkcLZEHivFsHSkZuSyD_0_xVz_M3YDJ7WW6vC3rt1Ct_r4LO7Qqlb5faOPb7kKdug |
link.rule.ids | 230,309,783,888,25576,76882 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfZ07T8MwEIBPVUGUDQqI8vSAskXEeZEOEUodpyk0D6Up6hY1cSp1KRUN4u9zidrCAptlS-eHdL77bN8Z4KFcaHN0NArZMvuarC9MKiNnUTnX54UQBhVlE5UWhKY_1V9mxqwFy10sTJMn9KtJjogaVaC-V81-vf45xHKbt5Wbx3yJVe_PXmq70paOkV8MVZHcgc3jyI2YxJjNHClMbI2i304tB0HpAD1sq_7sgL8N6qCU9W-L4p3AYYzCVtUptMpVFzps9_FaF46C7X03FreqtzkDaTiOZUoSznicRglxhlE4mqTECV0ynXCS-jzhkXcOxOMp82XsMNtPLmPOfmjaBbSR-ctLIKoQeZ8WyF6qphfIcJZAjhXF06IvFC0XPej9Kebqn7Z76PhpMM7Go_D1Go7rFauvwlXlBtrVx2d5ixa2yu-atfkGdCp52A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=GLP-1+RECEPTOR+AGONIST+AND+USE+THEREOF&rft.inventor=PARK%2C+JUNG-EUN&rft.inventor=AN%2C+KYUNG+MI&rft.inventor=KIM%2C+JEONG-GEUN&rft.inventor=HEO%2C+JAEHO&rft.inventor=YOO%2C+YEONGRAN&rft.inventor=SHIN%2C+JAE+EUI&rft.inventor=JEON%2C+WOO+JIN&rft.inventor=CHANG%2C+MIN+WHAN&rft.inventor=OH%2C+CHANGMOK&rft.inventor=JANG%2C+EUN+HYE&rft.inventor=KWON%2C+SUNG+WOOK&rft.inventor=LEE%2C+JIN+HEE&rft.inventor=KIM%2C+JUNG+HO&rft.inventor=IM%2C+A-RANG&rft.inventor=LEE%2C+MYONG+JAE&rft.inventor=CHOI%2C+JI+HYE&rft.inventor=JUN%2C+YEARIN&rft.inventor=HONG%2C+DA+HAE&rft.inventor=JE%2C+IN-GYU&rft.inventor=KIM%2C+KYEOJIN&rft.inventor=HONG%2C+CHANGHEE&rft.inventor=SOHN%2C+TE-IK&rft.inventor=KIM%2C+GUNHEE&rft.inventor=YOON%2C+HONG+CHUL&rft.inventor=JEONG%2C+JIN+AH&rft.date=2021-05-20&rft.externalDBID=A1&rft.externalDocID=CA3160518A1 |